L3VLUP
ProSign in

ARCT · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ARCTVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ARCT
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterARCTVRTX
Q3 20205 holders, $129m31 holders, $21.9bn
Q4 20201 holders, $172m30 holders, $18.4bn
Q1 20213 holders, $150m31 holders, $15.4bn
Q2 20211 holders, $98m30 holders, $12.7bn
Q3 20213 holders, $128m35 holders, $10.1bn
Q4 20212 holders, $93m28 holders, $12.4bn
Q1 20223 holders, $77m23 holders, $16.1bn
Q2 20223 holders, $61m25 holders, $18.1bn
Q3 20222 holders, $45m22 holders, $18.4bn
Q4 20222 holders, $47m28 holders, $18.4bn
Q1 20232 holders, $67m26 holders, $21.4bn
Q2 20232 holders, $85m27 holders, $24.7bn
Q3 20233 holders, $76m33 holders, $24.3bn
Q4 20234 holders, $111m32 holders, $28.6bn
Q1 20244 holders, $100m31 holders, $29.8bn
Q2 20243 holders, $73m29 holders, $33.4bn
Q3 20244 holders, $77m27 holders, $33.5bn
Q4 20244 holders, $62m26 holders, $28.5bn
Q1 20253 holders, $38m21 holders, $35.4bn
Q2 20253 holders, $43m21 holders, $32.3bn
Q3 20252 holders, $47m22 holders, $25.9bn
Q4 20251 holders, $16m26 holders, $31.8bn
Q1 20261 holders, $21m25 holders, $31.8bn
Q2 20261 holders, $19m26 holders, $34.6bn
ARCT

Arcturus Therapeutics LTD

Holders
4
Reported value
$77m
Buyers
4
Sellers
0

Breadth +4 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
27
Reported value
$33.5bn
Buyers
17
Sellers
10

Breadth +7 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 28 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ARCT (1)

PDT Partners LLC

Only VRTX (24)

AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Egerton Capital UK LLP, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →